Furthermore, blockade of eotaxin-2 by monoclonal antibody attenuated NASH and fibrosis in NAFLD animal models, thus suggesting a potential therapeutic role of anti-CCL24 agents in MASLD [161]. This evidence concerns the gene CCL24 and metabolic dysfunction-associated steatohepatitis.